ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?
Crossref DOI link: https://doi.org/10.1245/s10434-018-6833-7
Published Online: 2018-10-08
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dhir, Mashaal
Zureikat, Amer H.
Text and Data Mining valid from 2018-10-08
Article History
Received: 21 September 2018
First Online: 8 October 2018
Disclosure
: The authors have no conflicts of interest to disclose.